CT derived left atrial size identifies left heart disease in suspected pulmonary hypertension: Derivation and validation of predictive thresholds by Currie, BJ et al.
International Journal of Cardiology 260 (2018) 172–177
Contents lists available at ScienceDirect
International Journal of Cardiology
j ourna l homepage: www.e lsev ie r .com/ locate / i j ca rdCT derived left atrial size identiﬁes left heart disease in suspected
pulmonary hypertension: Derivation and validation of
predictive thresholdsBenjamin J. Currie a, Chris Johns a, MatthewChin a, Thanos Charalampopolous b, Charlie A. Elliot b, Pankaj Garg a,
Smitha Rajaram c, Catherine Hill c, Jim W. Wild a,d, Robin A. Condliffe b, David G. Kiely b,d, Andy J. Swift a,d,⁎
a Infection, Immunity and Cardiovascular Disease, University of Shefﬁeld, Shefﬁeld, UK
b Shefﬁeld Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Shefﬁeld, UK
c Radiology Department, Royal Hallamshire Hospital, Shefﬁeld, UK
d INSIGNEO, Institute for in silico medicine, University of Shefﬁeld, UK⁎ Corresponding author at: Academic Unit of Radiology
Royal Hallamshire Hospital, Glossop Road, Shefﬁeld, S10 2
E-mail address: a.j.swift@shefﬁeld.ac.uk (A.J. Swift).
https://doi.org/10.1016/j.ijcard.2018.02.114
0167-5273/© 2018 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 8 November 2017
Received in revised form 5 February 2018
Accepted 26 February 2018
Available online 4 March 2018Background: Patients with pulmonary hypertension due to left heart disease (PH-LHD) have overlapping clinical
features with pulmonary arterial hypertension making diagnosis reliant on right heart catheterization (RHC).
This study aimed to investigate computed tomography pulmonary angiography (CTPA) derived cardiopulmo-
nary structural metrics, in comparison to magnetic resonance imaging (MRI) for the diagnosis of left heart dis-
ease in patients with suspected pulmonary hypertension.
Methods: Patients with suspected pulmonary hypertension who underwent CTPA, MRI and RHC were identiﬁed.
Measurements of the cardiac chambers and vesselswere recorded fromCTPA andMRI. The diagnostic thresholds
of individual measurements to detect elevated pulmonary arterial wedge pressure (PAWP) were identiﬁed in a
derivation cohort (n= 235). Individual CT and MRI derived metrics were tested in validation cohort (n= 211).
Results: 446 patients, of which 88 had left heart disease. Left atrial area was a strong predictor of elevated
PAWPN15mmHg and PAWPN18 mmHg, area under curve (AUC) 0.854, and AUC 0.873 respectively. Similar ac-
curacy was also identiﬁed for MRI derived LA volume, AUC 0.852 and AUC 0.878 for PAWP N 15 and 18mmHg,
respectively. Left atrial area of 26.8 cm2 and 30.0 cm2were optimal speciﬁc thresholds for identiﬁcation of PAWP
N 15 and 18mmHg, had sensitivity of 60%/53% and speciﬁcity 89%/94%, respectively in a validation cohort.
Conclusions: CTPA and MRI derived left atrial size identiﬁes left heart disease in suspected pulmonary hyperten-
sionwith high speciﬁcity. The proposed diagnostic thresholds for elevated left atrial area on routine CTPAmay be
a useful to indicate the diagnosis of left heart disease in suspected pulmonary hypertension., University of Sh
JF, UK.
. This is an open© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
Pulmonary hypertension
Left heart disease
Left atrial area
Left atrial volume
Computed tomography pulmonary angiography
Magnetic resonance imaging1. Background
Pulmonary hypertension is a complex condition with multiple un-
derlying causes. It is deﬁned on right heart catheterisation (RHC) as a
resting mean pulmonary arterial pressure (mPAP) greater than or
equal to 25 mmHg, Of the 5 major World Health Organization (WHO)
classiﬁcations of Pulmonary Hypertension Group 2 pulmonary hyper-
tension due left heart disease (LHD) is themost common [1]. Unlike pul-
monary arterial hypertension (PAH) there are limited treatment
options in pulmonary hypertension due to left heart disease (PH-LHD)
[2,3]. A number of PAH approved therapies have proven to have no ben-
eﬁt or to be detrimental to a patient's survival when trialled in PH-LHDefﬁeld, Floor C,
access article under[4–6], thus treatment is focused on treating heart failure [3,5]. Despite
this, there is signiﬁcant interest in treatment of selected groups of pa-
tients in clinical trials [7–10].
A pulmonary arterial wedge pressure (PAWP) N 15 mm Hg along-
sidemPAP N 25mmHg is used to deﬁnePH-LHD. Both of these aremea-
sured on RHC, an invasive test with a 1% risk of serious complications. In
some instances PAWP has been shown to be poor indicator for Group 2
PH-LHD [11]. Some patients with PAWP 16–18 mm Hg have been
shown to have clinical features more suited to PAH [12]. Reliance on
RHC for diagnosis, often the ﬁnal investigation in the diagnostic algo-
rithm, results in increased risk to patients, a burden on resources and
loss of patients' time through referrals to tertiary centres [1].
CT pulmonary angiography is used routinely in the diagnostic algo-
rithm for pulmonary hypertension [1]. CT measurements such as in-
creased main pulmonary artery diameter and pulmonary artery to
aortic ratio have shown to predict the presence of pulmonarythe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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size have proven useful in identifying patients with PH-LHD [15–17].
However, no study has both derived and tested predictive thresholds of
CT metrics in separate derivation and validation cohorts to identify ele-
vated PAWP.
Therefore, the aim of the present studywas to assess howCT pulmo-
nary angiography derived metrics in isolation and as part of a derived
model, could be used to predict the presence of elevated PAWP. A fur-
ther aim was to assess the utility of CT measurements in comparison
to magnetic resonance imaging (MRI) imaging derived variables.
2. Methods
2.1. Patients
Consecutive patients with suspected pulmonary hypertension who underwent base-
line MRI and CT between 24th April 2012 and 30th March-2016 were identiﬁed from the
ASPIRE registry [18] (Assessing the Spectrum of Pulmonary hypertension Identiﬁed at a
Referral Centre). Patients were required to have MRI and CT within 3 months, and a diag-
nostic RHC. Sub-analysiswas performed in the patientswith suspected pulmonary arterial
hypertension or left heart disease. For this, patients with CT pulmonary angiogram evi-
dence of acute or chronic pulmonary emboli, at least moderate parenchymal lung disease
or known diagnosis with group 5 pulmonary hypertension were excluded. Ethical ap-
proval was granted from a local ethics committee for this retrospective study and written
consent was waived (ref c06/Q2308/8).
2.2. CT acquisition
CTpulmonary angiogramswere performedeither at the regional centreprior to trans-
fer or at the Shefﬁeld Pulmonary Vascular Disease Unit. CT pulmonary angiograms took
place in 66 different hospitals fromWales, Midlands and the north of England. The major-
ity of scans took place in Shefﬁeld (76.5%), the tertiary referral centre.
Shefﬁeld CT pulmonary angiograms were performed on a 64-slice MDCT scanner
(Light-Speed General Electric Medical Systems, Milwaukee, WI). The images studies
were not cardiac gated. Standard acquisition parameters were used: 100mA utilising au-
tomated dose reduction, 120 kV, pitch 1, rotation time of 0.5 s and 0.625mm collimation.
The ﬁeld of viewwas 400 × 400mm and the acquisition matrix was 512 × 512. 100ml of
intravenous contrast agent (Ultravist 300; Bayer Schering, Berlin, Germany)was adminis-
tered at 5 ml/s. HRCT images were also reconstructed from the contrast-enhanced acqui-
sitions using 1.25 mm collimation from the apex of the lung to the diaphragm. For all
studies slice thickness and number of slices were recorded. Limits were set at minimum
slice number of 50 and maximum slice thickness of 5 mm. Across the studies slice thick-
ness ranged from 0.5 mm to 5 mm with the mean slice thickness being 0.765 mm (SD
0.485). The minimum/maimium number of slices was 55/1001 with mean 434 (SD
117). Patients were excluded from the study if the images were not of diagnostic quality
as graded by a chest radiologist.
2.3. MR acquisition
CMR imaging was performed on a 1.5 T whole body scanner GE HDx (GE Healthcare,
Milwaukee, USA), using an 8-channel cardiac-coil, in supine position. Long axis LV 2-
chamber and 4-chamber CINE views were acquired. 4 chamber and short axis (SA) cine im-
ages were acquired using a retrospective cardiac gatedmulti-slice balanced steady state free
precession (bSSFP) sequence. A stack of axial images in the SAplanewith slice thickness of 8–
10mmwere acquired, fully covering both ventricles from base to apex. The bSSFP sequence
parameterswere: TR 2.8ms, TE 1.0ms, Flip angle of 50°, FOV=48×43.2, 256× 256matrix,
125 kHz bandwidth and slice thickness of 10mm.
2.4. CT image analysis
Image analysis was carried out with the observer blinded to right heart catheter data.
A detailed analysiswasperformed including; areameasurement of the 4 cardiac chambers
were made on axial images. The measurements were taken from the image where the
chamber visually appeared largest. On the image showing the maximal left atrial area,
the left atrial areawasmanually traced and the pulmonary veins and the atrial appendage
were excluded. For left atrial area the anterior-posterior diameterwas also recorded. Fig. 1
shows an example of the measurement of the left atrium. For ventricular measurements
the atrio-ventricular (AV) valves (mitral and tricuspid respectively) were visible on the
slice. The valve and mid transverse dimension were recorded for both ventricles on the
same slice as the area, along with the respective ventricular muscle areas. Maximal right
atrial area and transverse and longitudinal diameters were recorded.
Cardiac vesselmeasurements;main pulmonary artery (MPA) diameter, superior vena
cava (SVC) area, and ascending and descending aorta diameters were all recorded. These
measurementswere recorded on the slicewhere theMPA appearedwidest and bothmain
branches of the pulmonary artery were visible. Right and left main pulmonary artery di-
ameters were measured on separate slices were each appeared widest and roughly 1 cm
from the bifurcation. Pulmonary veins were measured separately at the respective widest
points as they enter the left atrium. A reconstructed 4 chamber view was created fromeach set of scans and themaximal area of each cardiac chamberwasmeasured. All diamet-
ric vesselmeasurementsweremade perpendicular to the direction of the vessel. All length
measurements were recorded in centimetres (cm) and all area measurements in
centimetres squared (cm2).
2.5. MR image analysis
Image analysis was undertaken on a GE AdvantageWorkstation 4.4 and GE Advantage
Workstation ReportCard. The MR observer was blinded to the patient clinical information
and cardiac catheter parameters. Scanswere deﬁned as non-diagnosticwhen image quality
signiﬁcantly affected cardiac measurements or, volumetric analysis could not be accurately
performed. LA volume was estimated using the well-established bi-plane area-length
method [19,20]. LV long axis (two chamber view) and four chamber views were analysed.
MRI LA measurements were taken at end-ventricular systole, equating to maximal atrial
size.LA volume was calculated from the relation: (0.85 × LA area two chamber view× LA
area four chamber view) / ((LA length two chamber+ LA length four chamber) / 2). The
CMR parameters were corrected where appropriate for body surface area (BSA), as previ-
ously reported in the literature [21,22].
2.6. Statistics
Histograms were constructed for the CT metrics to assess for normal distribution.
Mean and standard deviationwere used for normally distributed data.Where appropriate
Pearson correlation coefﬁcients were calculated for CT-derivedmetrics versus PAWP. Cat-
egorical and continuous data were compared between the PAWP ≤ 15mmHg and PAWP
N 15mmHg groups using Chi-square and independent t-test respectively. The patient co-
hort was split into two randomly constructed cohorts (derivation and validation). These
two cohorts were also compared using t-tests and Pearson Chi-square tests.
In the derivation cohort, candidate differentiators predictive at univariate analysis
with p b 0.05 were entered into a binary logistic regression to detect PAWP N 15mmHg
using forward selection. Receiver operating characteristic (ROC) analysis was performed
to determine diagnostic accuracy of candidate CT metrics with area under the ROC curve
(AUC) results presented. Chi-square and Fishers exact test were used to calculate sensitiv-
ity, speciﬁcity, positive and negative predictive values. Predictive thresholds for univariate
CT metrics with high speciﬁcity were chosen for identiﬁcation of elevated PAWP (both
PAWP N 15 and PAWP N 18) in the derivation cohort and were tested in the validation co-
hort. MRI derived left atrial volume was correlated with CT metrics and discriminatory
ability of CT and MRI at ROC analysis compared. For these same variables, ROC analysis
was undertaken in the whole cohort to predict howwell these MRI-derived variables dis-
criminated increased PAWP N 15mmHg and N18mmHg. 15 patients were analysed sep-
arately by two observers to determine interobserver variability and one of the observers
repeated analysis on 15 patients to assess for intraobserver variability.
All statistics were performed in SPSS 21 (IMB, Chicago) and all graphs were produced
using GraphPad, Prism (GraphPad, San Diego). A p-value of b 0.05 was considered statisti-
cally signiﬁcant.3. Results
Four-hundred forty-six (446) patients with suspected pulmonary
hypertension were identiﬁed who underwent MRI, CT and RHC (includ-
ing PAWPmeasurement)within period studied. 381 patients had pulmo-
nary hypertension. Mean age 64.0 (SD 13), 170 Males: 276 Females.
Table 1, shows demographic data and CT derived measurements for
the study and compares those with PAWP N 15 mmHg to those
with PAWP ≤ 15 mmHg. The mean interval between CT and RHC was
18 days (SD 44). 231 patients were identiﬁed for subgroup analysis
with suspected pulmonary arterial hypertension or pulmonary hyperten-
sion owing to left heart disease.
3.1. Association to invasive PAWP
Left atrial area showed the strongest correlation with PAWP, r =
0.525, p b 0.001 a scatter plot is provided Fig. 2. The following met-
rics also correlated with PAWP; left atrial anterior posterior
diameter, r = 0.509, p b 0.001, total pulmonary vein area, r =
0.323, p b 0.001, RV/LA area ratio, r = −0.322, p b 0.001, left ven-
tricular muscle area, r = 0.230, p b 0.001, right atrial area, r =
0.225, p b 0.001 and left ventricular area, r = 0.221, p b 0.001. MRI
derived LA volume correlated most strongly with CT derived LA
area, r = 0.836, p b 0.001. 4 chamber LA area reconstructed had a
marginally weaker correlation with LA volume on MRI, r = 0.815,
p b 0.001. All measured variables were normally distributed.
Fig. 1. LA area region of interests in a patient with idiopathic pulmonary arterial hypertension (left) and a patient with pulmonary hypertension associated with left heart disease (right).
Table 1
Demographics and CTPA derived metrics.
PAWP ≤
15 mm Hg
n = 358
PAWP N
15 mm Hg
n = 88
P-value
Age (years) 62.5 (13.4) 70 (8.7) b0.001
Sex F 222 (62%) 54 (61.4%) 0.911
M 136 (38%) 34 (38.6%)
Body surface
area (m2)
1.82 (0.24) 1.87 (0.21) 0.099
WHO functional class I 0 1 (1.1%) 0.073
II 49 (14%) 8 (9.1%)
III 267 (76.5%) 74 (84.1%)
IV 33 (9.5%) 5 (5.7%)
ISWT walking
distance (m)
231 (201) 183 (160) 0.057
Right heart catheter mPAP (mm Hg) 40 (15) 41 (12) 0.609
mRAP (mm Hg) 9 (5) 14 (5) b0.001
PAWP
(mmHg)
11 (3) 21 (5) b0.001
SVO2 (%) 65.4 (8.4) 64.7 (9.3) 0.514
PVR (dyn·s/cm5) 572 (409) 354 (268) b0.001
CO (L/min) 4.91 (1.59) 4.99 (1.46) 0.662
CI (L/min/m2) 2.70 (0.84) 2.68 (0.76) 0.782
RV area (cm2) 28.3 (9.39) 28.7 (8.92) 0.747
RV muscle area (cm2) 3.92 (1.76) 3.75 (1.72) 0.404
RA area (cm2) 28 (10.9) 35.5 (1.30) b0.001
LV area (cm2) 20.9 (6.86) 24.4 (8.03) b0.001
LV muscle area (cm2) 15.5 (4.06) 17.3 (5.54) b0.001
LA area (cm2) 19.6 (5.88) 29.5 (8.06) b0.001
LA anterior-posterior
diameter (cm)
3.68 (0.78) 4.79 (0.83) b0.001
MPA diameter (cm) 3.15 (0.58) 3.21 (0.50) 0.397
Ascending aorta
diameter (cm)
3.1 (0.43) 3.32 (0.47) b0.001
SVC area (cm2) 3.54 (1.22) 4.41 (1.52) b0.001
Total PV area (cm2) 4.72 (1.85) 6.19 (2.48) b0.001
Total PV/MPA area
ratio
0.65 (0.32) 0.79 (0.32) b0.001
RV/LV area ratio 1.52 (0.80_ 1.29 (0.58) 0.011
RV/LV muscle area
ratio
0.27 (0.14) 0.23 (0.12) 0.028
RA/LA area ratio 1.51 (0.67) 1.22 (0.38) b0.001
RV/LA area ratio 1.55 (0.67) 1.02 (0.39) b0.001
Coronary calciﬁcation Y 157 (43.9%) 57 (64.8%) 0.002
N 200 (55.9%) 31 (35.2%)
Aortic annulus
calciﬁcation
Y 80 (22.3%) 33 (37.5%) 0.013
N 277 (77.4%) 55 (62.5%)
Mitral annulus
calciﬁcation
Y 35 (9.8%) 22 (25%) b0.001
N 322 (89.9%) 66 (75%)
Abbreviations: WHO-World Health Organisation, mPAP-mean Pulmonary Artery Pres-
sure, mRAP-mean Right Atrial Pressure, PAWP-Pulmonary Arterial Wedge Pressure,
SVO2-Mixed Venous Oxygen Saturation, PVR-Pulmonary Vascular Resistance, CO-Cardiac
Output, CI-Cardiac Index, ISWT-Incremental ShuttleWalking Test, RV-Right Ventricle, RA-
Right Area, LV-Left Ventricle, LA-Left Atrial, MPA-Main Pulmonary Artery, SVC-Superior
Vena Cava, PV-Pulmonary Vein.
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Supplementary Table 1 presents the demographic data for the deriva-
tion and validation cohorts. Therewas no signiﬁcant difference in the de-
mographics between the cohorts. Fig. 2 presents ROC curves of 4 key CT
derived variables and in the whole patient cohort; LA area AUC= 0.854,
p b 0.001, LA/RV area ratio AUC= 0.757, p b 0.001, Total PV area AUC=
0.681, p b 0.001, LA/RA area ratio AUC= 0.601, p=0.002.
The results of multivariate analysis for differentiating PAWP≤15
mmHg and PAWP N 15 mmHg showed left atrial area was the only in-
dependent predictor of elevated PAWP (p b 0.001), with no additive
value of other CT metrics.
In Table 2 the results of ROC analysis in validation cohort of CT and
MRI derived left atrial measurements using both 15 mm Hg and 18
mmHg as limits for elevated PAWP.
Speciﬁc thresholds for left atrial area identiﬁed in the derivation co-
hort through assessment of the ROC coordinate plots. The thresholds
identiﬁed were 26.8 cm2 and 30 cm2 for PAWP N 15 mm Hg and 18
mm Hg respectively. Supplementary Table 3 shows the sensitivities
and speciﬁcities of all 4 thresholds when tested in the respective valida-
tion cohorts. In the validation cohort 26.8 cm2 were 89% speciﬁc, sensi-
tivity wasmarginally higher at 60% for detecting PAWP N 15, versus 53%
for detecting PAWP N 18.
MRI derived left atrial volume was the most accurate MRI variable
for predicting PAWP N 15 (AUC = 0.852, p b 0.001), similar to CT-
derived LA area AUC= 0.858, p b 0.001. 4-Chamber reconstructed LA
area had an AUC of 0.805, p b 0.001 in the validation cohort which
was inferior to LA area measured axially.3.3. Subgroup analysis
In the 231 patients with suspected PAH or left heart disease, the accu-
racy for predicting PAWP N 18 for left atrial area was higher with area
under the curve 0.907 (p b 0.001) versus PAWP N 15 for which the area
under the curve was 0.874 (p b 0.001). Baseline demographics for the
subgroup derivation and validation cohorts are shown in Supplementary
Table 2 which demonstrates no signiﬁcant difference between the two
cohorts. The thresholds of 27.1 cm2 and 30.3 cm2 for 15 and 18 respec-
tively found from the derivation cohort in the subgroup analysis. The sub-
group analysis showed higher speciﬁcity particularly in the PAWP N 18
mmHg analysis with speciﬁcity 95%. Sensitivity was marginally higher
at 65% for detecting PAWP N 15, versus 60% for detecting PAWP N 18.3.4. Reproducibility
Inter-observer reproducibility for the key variables is shown
in Supplementary Table 4. Left atrial area and left atrial AP dimen-
sion showed excellent inter-observer reproducibility, ICC = 0.972,
Fig. 2. Correlation of left atrial (LA) area and pulmonary arterial wedge pressure (PAWP), left. And right, receiver operating characteristic curves for LA area, LA/RV area, Total PV area and
LA/RA area ratio, AUC 0.854, 0.757, 0.681 and 0.601, respectively.
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lation for left atrial was 0.963, p b 0.001.
4. Discussion
CT derived left atrial area is a strong and independent predictor of in-
creased PAWP in patients with suspected pulmonary hypertension. En-
larged left atrial area using thresholds of 26.8 cm2 and 30.0 cm2 to
predict Group 2 pulmonary hypertension due to PAWP N 15 mm Hg
and PAWP N 18 mm Hg respectively had a speciﬁcity of 89% and 94%
in a separate validation cohort. In a subgroup analysis of only those pa-
tients with suspected PAH and PH-LHD, to identify PAWPN18mmHg a
30.3 cm2 threshold for LA areawas95% speciﬁc. The studydemonstrates
increased PAWP can be identiﬁed to a high degree of speciﬁcity using CT
derived LA area and may support the diagnosis of left heart disease in
suspected pulmonary hypertension alongside clinical assessment.
When left atrial area was measured using 4-chamber reconstruction
the area under the curve wasmarginally inferior to whenmeasured ax-
ially, one possible explanation is error in identifying an optimal 4 cham-
ber view on reconstruction.
In this study of 446 patients with suspected pulmonary hyperten-
sion, we show that left atrial (LA) area is the most predictive CT mea-
surement for the detection of a raised pulmonary artery wedge
pressure. A threshold of 30 cm2 had 94% speciﬁcity to detect elevated
PAWP N18 mm Hg in the full validation cohort. Previously, identiﬁedTable 2
Results of ROC analysis in validation cohort for LA measurements in CT and MRI derived
variables at PAWPN15mmHg and PAWPN18mmHg.
Area under curve
(Standard deviation)
P-value
CT metrics for PAWP N 15 mm Hg
LA area 0.858 (0.034) b0.001
LA area BSA indexed 0.848 (0.037) b0.001
LA anterior-posterior diameter 0.834 (0.035) b0.001
MRI metrics for PAWP N 15 mm Hg
LA 2ch area 0.833 (0.037) b0.001
LA 4ch area 0.851 (0.035) b0.001
LA volume 0.852 (0.036) b0.001
LA volume BSA indexed 0.843 (0.041) b0.001
CT metrics for PAWP N 18 mm Hg
LA area 0.873 (0.036) b0.001
LA area BSA indexed 0.855 (0.042) b0.001
LA anterior-posterior diameter 0.842 (0.038) b0.001
MRI metrics for PAWP N 18 mm Hg
LA 2ch area 0.868 (0.034) b0.001
LA 4ch area 0.857 (0.038) b0.001
LA volume 0.878 (0.034) b0.001
LA volume BSA indexed 0.865 (0.041) b0.001
Abbreviations: PAWP-Pulmonary ArterialWedge Pressure, LA-Left Atrium, BSA-Body Sur-
face Area, CT-Computed Tomography, MRI-Magnetic Resonance Imaging.candidate LA markers: LA/right atrium ratio, LA/right ventricle and LA/
body surface area, were all of weaker diagnostic accuracy compared to
LA area. A regression model comprising a number of CT metrics did
not adddiagnostic value over LA area alone.Whenpatientswith chronic
thromboembolic disease, at least moderate lung disease and known
miscellaneous causes of PH were excluded the accuracy marginally for
detection of PAWP N 15 and PAWP N 18 respectively. CT derived LA
area was equally accurate for predicting elevated PAWP compared to
MRI derived left atrial volume. The inter-observer correlation of LA
area was excellent.
LA area has previously been shown to predict the presence of ele-
vated PAWP in selected populations [15–17]. Safdar et al. [15], showed
a correlation of r= 0.45 was between LA area and PAWP, marginally
weaker than in the present study. Katikreddy et al. [16], found LA area
to be a predictor of the presence of LHD in PH, with area under the
curve at ROC analysis of 0.76 compared with 0.85 in the present study.
Juivraj et al. [17] found the area under curve for LA area to predict PH
in LHD was also lower at 0.73.
Thresholds for enlarged LA area to identify elevated PAWP have pre-
viously been identiﬁed, these range from20 cm2 to 31 cm2 [15–17]. Until
now, no studies have validated these derived thresholds in separate co-
horts. In this study, highly speciﬁc thresholds were sought, and LA area
of 26.8 cm2 and 30.0 cm2 were identiﬁed to predict PAWP N 15 mmHg
and PAWPN18mmHg, respectively. For predicting elevated PAWP N 15
in the validation cohort there was a sensitivity of 60% and speciﬁcity of
89%. In the 30.0 cm2 threshold for PAWP N 18 mm Hg sensitivity was
53% and speciﬁcity 94% in the validation cohort. Safdar et al. [15] chose
30 cm2 as a threshold, for which sensitivities and speciﬁcities were not
calculated but this was highly accurate on ROC analysis, with an area
under the curve of 0.996. Jivraj et al. [17], selected a left atrial area of
24 cm2, prioritising speciﬁcity over sensitivity, with a the sensitivity
was 44% and speciﬁcity 93%. A threshold of 20 cm2 was selected by
Katikreddy et al. [16]. Sensitivity and speciﬁcity were not recorded at
this threshold as instead they were calculated by combining LA area N
20 cm2 with normal RV area and were 77% and 94%, respectively. How-
ever, in the present study the LA area/RV area ratio was of weaker accu-
racy than LA area alone, AUC= 0.757 versus AUC= 0.854 respectively.
We postulate that RV size does not aid the differentiation of pre and
post capillary pulmonary hypertension given that the RV can increase
in size in both conditions to a variable degree. Prior studies have not di-
rectly compared sensitivity/speciﬁcity analysis of CT measured LA area
alone versus LA area adjusted for RV. LA area/RA area has also been
shown to have diagnostic value and it is postulated correcting for RA
area will account for the variation in volume of the LA during the cardiac
cycle (INSERT reference here 27573596 international journal of cardiol-
ogy, as per reviewer 1). However in the present study LA area alone de-
spite the potential inaccuracy due to variation with cardiac phase was
the most predictive measurement for the diagnosis of left heart disease.
CTPA has high sensitivity and speciﬁcity in detecting thromboem-
bolic disease and shown to be of equal beneﬁt in diagnosis as V/Q
176 B.J. Currie et al. / International Journal of Cardiology 260 (2018) 172–177scintigraphy [23]. Moderate lung disease can be assessed and identiﬁed
using pulmonary function tests, X-ray and CT ﬁndings [24]. A number of
haematological, systemic and metabolic conditions are associated with
miscellaneous Group 5 PH25. In the subgroup analysis, excluding pa-
tients with known clinical and CT features of chronic thromboembolic
disease, at least moderate lung disease or a known diagnosis that
meets criteria for group 5 PH, we found marginally improved the effec-
tiveness of LA area to identify patients for increased PAWP. This repre-
sents a clinically relevant diagnostic dilemma, where it may be
challenging to differentiate PAH from PH-LHD.
Using a threshold of 30.3 cm to identify PAWP N 18 mm Hg gave a
speciﬁcity of 95% in the validation cohort. Thismay represent a clinically
relevant complementary tool to aid the referral pathway and reduce un-
necessary referrals of patientswith signiﬁcantly elevated left ventricular
ﬁlling pressure.
An advantage of this study is the use of derivation and validation co-
horts to produce predictive thresholds using ROC analysis and then de-
termine their accuracy in a separate, independent cohort. In all previous
studies the deﬁned limit for elevated PAWPwas N15 mmHg as deﬁned
in the recent guidelines [24]. In this study, the thresholds of enlarged LA
area were set using a higher limit of PAWP N 18 mm Hg, as well as
PAWP N 15mmHg. Studies have shown that there are a number of pa-
tients with PAH that have elevated PAWP between 15 and 18 mm Hg
[12,26]. In the ASPIRE registry study, 20 patients were shown to have
a clear phenotype of pulmonary arterial hypertension (PAH) but their
PAWP was between 16 and 18 mmHg18.
Speciﬁcity was prioritised over sensitivity, as it was the aim to iden-
tify those patients with left heart disease before right heart catheter to
prevent unnecessary investigations and management. The borderline
patients and those who more likely had other forms of pulmonary hy-
pertension would not be identiﬁed due to lower sensitivity and would
require further investigations as we would not wish to exclude these
patients from potential beneﬁcial treatment available for other forms
of pulmonary hypertension such as PAH [2]. A further advantage of
this study is the inclusion of 105 cases from different hospitals within
the referral area, suggesting that these results are applicable acrossmul-
tiple centres.
Non-invasive identiﬁcation of elevated PAWP using echocardiogra-
phy and clinical assessment has been shown to be effective in discrimi-
nating Group 2 PH27. In Jacobs et al. [27], medical history, ECG and
Echocardiography variables were combined to from a model to predict
PH-LHD. This model was found to have an area under the curve of
0.93. As with this study Crawley et al. [28] demonstrated LA volume to
be the most signiﬁcant MRI derived variable to identify Group 2 PH
though in a population of just those patients with IPAH and PH-HFpEF
with AUC = 0.990, p b 0.001. A threshold of LA volume N 43 ml/m2
had 97% sensitivity and 100% speciﬁcity [28]. In contrast in our study
of patients with suspected PH, MRI derived LA volume was of weaker
accuracy (AUC= 0.844, p b 0.001) which was equivalent to CT derived
LA area (AUC= 0.854, p b 0.001).
4.1. Limitations
A signiﬁcant limitation is the retrospective study design of this study
and potential selection bias. Prospective recruitment of patients to un-
dergo, CT, MRI and RHC is advised to validate the ﬁndings of this
study. In addition, evaluation in a second centre would be of value.
This studywas performedusing non-cardiac gated CT pulmonary angio-
grams performed in the routine assessment of patients with suspected
PH. ECG-gating may improve the repeatability and accuracy of LA area
measurements [29]. The disadvantage of cardiac gated CT is it is associ-
ated with higher radiation dose [30] and is not routinely performed in
patients with suspected pulmonary hypertension. Automated volumet-
ric measurements of cardiac chambers have been used to predict Group
2 PH-LHD [31]. The use of automated volumetric chamber software is
not in widespread use. Further studies evaluating such techniques inlarger cohorts are warranted. Another limitation was 23% of the CTPAs
were acquired from 66 different hospitals, so there was variation in
the CT scanner used. This resulted in disparity between the slice thick-
nesses reconstructed at each centre and meant images were of varying
quality, however this reﬂects a clinically relevant referral population.
The number of patients with elevated PAWP is relatively small 88
with PAWP N 15 and 54 PAWP N 18, further study in larger patient co-
horts likely in a multicenter setting is advised.
4.2. Clinical implications
There are broader clinical applications of the present study. CTPA is
mainly done in emergency medicine. CT-derived LA area can easily be
integrated in routine CTPA reporting. An estimate of PAWP, a surrogate
of the left ventricular ﬁlling pressure, can guide towards more precise
diagnosis. We do not propose LA area as a substitute for PAWP, rather
a screening too to be used alongside a detailed clinical evaluation. As
the main symptom of these patients is shortness of breath, appropriate
further tests, including echocardiogram can help to conﬁrm the diagno-
sis of LHD or heart failure with preserved ejection fraction.
5. Conclusions
CT derived left atrial area is a strong and independent predictor of in-
creased PAWP in patients with suspected pulmonary hypertension. En-
larged left atrial area using thresholds of 26.8 cm2 and 30.0 cm2 to
predict Group 2 pulmonary hypertension due to PAWP N 15 mm Hg
and PAWP N 18 mm Hg respectively had a speciﬁcity of 89% and 94%
in a validation cohort. In a subgroup analysis of only those patients
with suspected PAH and PH-LHD, to identify PAWPN18 mmHg a 30.3
cm2 threshold for LA area was 95% speciﬁc. The study demonstrates in-
creased PAWP can be identiﬁed to a high degree of speciﬁcity using CT
derived LA area.
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